Keyword search (3,936 papers available)


Stimulus-Responsive Degradable Polylactide-Based Block Copolymer Nanoassemblies for Controlled/Enhanced Drug Delivery.

Author(s): Bawa KK, Oh JK

Mol Pharm. 2017 08 07;14(8):2460-2474 Authors: Bawa KK, Oh JK

Article GUID: 28493712
PLA-Based Triblock Copolymer Micelles Exhibiting Dual Acidic pH/Reduction Responses at Dual Core and Core/Corona Interface Locations.

Author(s): Bawa KK, Jazani AM, Shetty C, Oh JK

Macromol Rapid Commun. 2018 Dec;39(24):e1800477 Authors: Bawa KK, Jazani AM, Shetty C, Oh JK

Article GUID: 30286258
Title:Stimulus-Responsive Degradable Polylactide-Based Block Copolymer Nanoassemblies for Controlled/Enhanced Drug Delivery.
Authors:Bawa KK,  Oh JK
Link:https://www.ncbi.nlm.nih.gov/pubmed/28493712?dopt=Abstract
Category:Mol Pharm
PMID:28493712
Dept Affiliation: CHEMBIOCHEM
1 Department of Chemistry and Biochemistry, Concordia University , Montreal, Quebec, Canada H4B 1R6.

Description:

Stimulus-Responsive Degradable Polylactide-Based Block Copolymer Nanoassemblies for Controlled/Enhanced Drug Delivery.

Mol Pharm. 2017 08 07;14(8):2460-2474

Authors: Bawa KK, Oh JK

Abstract

Polylactide (PLA) is biocompatible and FDA-approved for clinical use and thus has been a choice of the materials valuable for extensive applications in biomedical fields. However, conventionally designed PLA-based amphiphilic block copolymer (ABP) nanoassemblies exhibit slow and uncontrolled release of encapsulated drugs because of the slow biodegradation of hydrophobic PLA in physiological conditions. To improve potentials for clinical use and commercialization of conventional PLA-based nanoassemblies, stimulus-responsive degradation (SRD) platform has been introduced into the design of PLA-based nanoassemblies for enhanced/controlled release of encapsulated drugs. This review summarizes recent strategies that allow for the development of PLA-based ABPs and their self-assembled nanostructures exhibiting SRD-induced enhanced drug release. The review focuses on the design, synthesis, and evaluation of the nanoassemblies as intracellular drug delivery nanocarriers for cancer therapy. Further, the outlook is briefly discussed on the important aspects for the current and future development of more effective SRD PLA-based nanoassemblies toward tumor-targeting intracellular drug delivery.

PMID: 28493712 [PubMed - indexed for MEDLINE]